You are here: Industry Insights > depressive disorder

News List

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder drugs
August 25, 2021
Axsome Therapeutics,today announced that the U.S. Food and Drug Administration (FDA) informed the Company in a teleconference on August 20, 2021, that its review of the new drug application (NDA) for AXS-05 for the treatment of major depressive disorder .
CDISC Announces New Standard for Major Depressive Disorder to Foster Development of New Treatments americanpharmaceuticalreview
April 20, 2017
The Clinical Data Interchange Standards Consortium (CDISC) has released the Major Depressive Disorder (MDD) Therapeutic Area User Guide v1.0.
d-Methadone for Adjunctive Treatment of Major Depressive Disorder Fast Tracked by FDA americanpharmaceuticalreview
April 14, 2017
Relmada Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for d-Methadone (REL-1017 dextromethadone).
Hikma launches desvenlafaxine succinate extended-release tablets in the US market cphi-online
March 14, 2017
The tablets are indicated for the treatment of major depressive disorder.